Adial Competitors

Stocks . USA . 
Stock . Adial Pharmaceuticals
ADIL Stock  USD 0.23  0.01  4.17%   
Adial Pharmaceuticals competes with Neurosense Therapeutics, Acurx Pharmaceuticals, Matinas BioPharma, Brainstorm Cell, and Aprea Therapeutics; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Adial Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Adial Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Adial Pharmaceuticals Correlation with its peers.
For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Adial Pharmaceuticals competition on your existing holdings.
  
Build AI portfolio with Adial Stock
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.010.234.03
Details
Intrinsic
Valuation
LowRealHigh
0.010.224.02
Details
Naive
Forecast
LowNextHigh
00.214.00
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.210.280.35
Details

Adial Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Adial Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Adial and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Adial Pharmaceuticals does not affect the price movement of the other competitor.

Risk-Adjusted Indicators

There is a big difference between Adial Stock performing well and Adial Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Adial Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
NRSN  3.52 (0.47) 0.00  0.43  0.00 
 0.00 
 7.89 
(7.37)
 34.62 
ACXP  6.15  0.34  0.01 (0.06) 5.37 
(9.54)
 10.99 
(9.34)
 99.56 
MTNB  4.70 (1.60) 0.00 (1.37) 0.00 
 0.00 
 7.60 
(10.14)
 39.32 
BCLI  3.10  0.11  0.00  0.01  0.00 
 0.00 
 7.14 
(5.71)
 20.30 
APRE  2.97 (0.56) 0.00  3.19  0.00 
 0.00 
 4.40 
(8.40)
 17.87 
HCWB  4.49 (1.29) 0.00 (4.08) 0.00 
 0.00 
 8.72 
(10.57)
 42.33 
KPRX  2.64 (0.46) 0.00  3.19  0.00 
 0.00 
 5.32 
(6.25)
 21.80 
CDIO  4.53 (0.04) 0.00  0.14  0.00 
 0.00 
 8.44 
(9.05)
 35.76 
CELZ  4.44 (0.46) 0.00  1.50  0.00 
 0.00 
 8.54 
(10.70)
 50.90 
BCDA  2.85  0.16 (0.01)(0.03) 3.44 
(3.42)
 7.03 
(5.76)
 23.03 
All Fundamental Data

Adial Pharmaceuticals Competitive Analysis

The better you understand Adial Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Adial Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Adial Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ADIL NRSN ACXP MTNB BCLI APRE HCWB KPRX CDIO CELZ
 4.17 
 0.23 
Adial
 2.44 
 0.80 
Neurosense
 7.80 
 3.19 
Acurx
 10.14 
 0.62 
Matinas
 13.56 
 0.67 
Brainstorm
 3.16 
 0.98 
Aprea
 4.70 
 1.42 
HCW
 3.90 
 1.97 
Kiora
 2.63 
 3.33 
Cardio
 5.41 
 2.10 
Creative
Market Volatility
(90 Days Market Risk)
Out of control
Risky
Moderately volatile
Moderately volatile
Relatively risky
Very risky
Moderately volatile
Relatively risky
Somewhat reliable
Unstable
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Risky
High
Risky
Risky
Small
Risky
Risky
Low
Risky
Strong
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
5.32
15.09
19.43
7.79
1.63
7.45
30.25
1.53
18.42
58.88
Net Asset
5.04 M
4.58 M
3.86 M
12.64 M
1.83 M
23.98 M
30.24 M
36.48 M
10.62 M
6.67 M
EBITDA
(8.28 M)
(9.88 M)
(14.1 M)
(19.19 M)
(11.31 M)
(14.3 M)
(27.68 M)
5.7 M
(8.09 M)
(5.63 M)
Current Valuation
1.59 M
20.45 M
745.5 K
867.63 K
7.78 M
(6.86 M)
9.55 M
(11.73 M)
212.13 K
1.96 M
Price To Book
1.38
12.82
1.83
0.61
65.82
0.63
2.8
0.32
0.75
1.31
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
-528.87
N/A
-599.51
N/A
Retained Earnings
(82 M)
(36.66 M)
(67.32 M)
(199.82 M)
(226.64 M)
(321.04 M)
(100.56 M)
(143.38 M)
(22.75 M)
(64.59 M)
Current Asset
1.02 M
N/A
N/A
6.53 M
16.79 M
39.28 M
N/A
N/A
N/A
N/A
Beta
1.11
1.57
-1.25
1.33
0.53
1.57
0.64
-0.75
2.87
5.86
Number Of Employees
5
17
4
3
23
8
36
12
13
4
Shares Outstanding
26.65 M
29.55 M
2.09 M
6.41 M
11.03 M
6.99 M
2.15 M
3.68 M
1.83 M
3.49 M
Cash Flow From Operations
(6.92 M)
(10.13 M)
(10.38 M)
(15.88 M)
(9.09 M)
(13.56 M)
(14.23 M)
8.56 M
(4.99 M)
(5.3 M)
Total Debt
975.86 K
73 K
3.24 M
2.89 M
720 K
4.67 M
13.69 M
57.17 K
969.86 K
14.19 K
Return On Equity
-1.55
-24.78
-2.91
-1.52
-11.22
-0.75
-277.26
-0.33
-1.11
-0.98
Return On Asset
-0.79
-3.04
-0.96
-0.39
-4.0
-0.42
-0.3
-0.17
-0.62
-0.6
Number Of Shares Shorted
407.42 K
681.15 K
98.25 K
11.07 K
604.46 K
34.58 K
62.74 K
16.67 K
2.19 K
77.02 K
Book Value Per Share
0.19
-0.021
2.02
1.1
-0.7
1.83
-0.024
6.53
4.61
2.17
Current Liabilities
452.53 K
N/A
N/A
1.36 M
2.95 M
5.96 M
N/A
N/A
N/A
N/A
Total Asset
5.04 M
4.58 M
3.86 M
12.64 M
1.83 M
23.98 M
30.24 M
36.48 M
10.62 M
6.67 M
Debt To Equity
0.029
0.019
0.026
0.1
0.6
0.005
0.005
0.018
N/A
N/A
Short Ratio
1.12
1.15
1.23
0.33
1.27
0.48
0.54
0.33
0.07
0.8
Target Price
2.17
11.5
61.7
30.0
17.0
7.0
35.0
12.0
60.0
20.0
Shares Owned By Institutions
3.94
1.71
7.03
5.32
0.02
25.68
2.24
19.58
6.3
5.9
Market Capitalization
6.2 M
27.11 M
6.65 M
3.97 M
7.39 M
6.86 M
5.36 M
7.25 M
6.08 M
7.34 M
Price To Earning
-1.88
N/A
N/A
-2.43
-16.0
-9.54
N/A
N/A
N/A
-54.81
Price To Sales
N/A
N/A
N/A
46.5
N/A
14.04
9.09
363.74
385.3
1223.13
Net Income
(13.2 M)
(10.21 M)
(14.1 M)
(24.25 M)
(11.62 M)
(12.96 M)
(30.02 M)
3.59 M
(8.38 M)
(5.49 M)
Earnings Per Share
-0.6
-0.36
-8.18
-3.42
-1.42
-2.12
-16.41
-2.19
-11.91
-2.84
Shares Owned By Insiders
2.24
25.55
6.16
22.11
11.21
21.65
27.3
2.98
6.79
1.0
Revenue
N/A
N/A
N/A
N/A
849 K
1.5 M
2.57 M
16 M
34.89 K
11 K
Working Capital
3.08 M
2.41 M
615.12 K
5.36 M
(8.59 M)
20.22 M
(23.93 M)
23.7 M
8.16 M
5.81 M
Cash And Equivalents
9.16 M
10.37 M
9.09 M
38.5 M
12.24 M
39.06 M
32.41 M
2.43 M
9.66 M
22.86 M
Cash Per Share
0.35
0.89
0.8
0.18
0.34
1.67
0.9
2.64
5.08
1.62
Gross Profit
N/A
N/A
N/A
(2.46 M)
N/A
(7.91 M)
166.57 K
(3.72 M)
15.78 K
3.6 K
Day Typical Price
0.24
0.8
3.27
0.64
0.64
0.99
1.42
1.98
3.37
2.13
Accumulation Distribution
0.08
0.0833
0.0756
0.15
0.18
0.0588
0.11
0.015
0.0712
0.0543
Market Facilitation Index
0.02
0.07
0.26
0.11
0.12
0.06
0.16
0.03
0.25
0.12
Daily Balance Of Power
(0.50)
(0.29)
(1.04)
(0.64)
0.6667
0.5
(0.44)
(2.67)
(0.36)
(1.00)
Period Momentum Indicator
(0.01)
(0.02)
(0.27)
(0.07)
0.08
0.03
(0.07)
(0.08)
(0.09)
(0.12)
Rate Of Daily Change
0.96
0.98
0.92
0.9
1.14
1.03
0.95
0.96
0.97
0.95
Day Median Price
0.24
0.81
3.31
0.66
0.62
0.99
1.42
1.99
3.39
2.15
Price Action Indicator
(0.01)
(0.01)
(0.26)
(0.07)
0.09
0.005
(0.04)
(0.06)
(0.10)
(0.11)
Relative Strength Index
39.66
37.21
48.21
35.01
37.04
31.71
33.16
49.92
52.41
33.63
Coefficient Of Variation
(652.14)
(910.01)
8164.3
(425.02)
(129,743)
(697.46)
(538.77)
(819.59)
(7,488)
(1,433)
Mean Deviation
2.82
3.52
6.15
4.7
3.1
2.97
4.49
2.64
4.53
4.44
Jensen Alpha
(0.60)
(0.47)
0.3381
(1.60)
0.1102
(0.56)
(1.29)
(0.46)
(0.04)
(0.46)
Total Risk Alpha
(1.00)
(1.13)
(1.27)
(2.20)
(0.47)
(1.00)
(2.00)
(0.88)
(0.80)
(1.21)
Sortino Ratio
N/A
N/A
0.0136
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Downside Variance
N/A
N/A
32.03
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Standard Deviation
3.8
5.15
13.26
6.4
4.25
3.93
6.78
3.82
6.54
6.76
Kurtosis
0.2173
3.85
32.91
6.37
1.2
0.6373
3.41
2.43
2.77
7.9
Potential Upside
5.56
7.89
10.99
7.6
7.14
4.4
8.72
5.32
8.44
8.54
Treynor Ratio
(4.57)
0.4268
(0.06)
(1.37)
0.0081
3.19
(4.08)
3.19
0.1382
1.5
Maximum Drawdown
18.11
34.62
99.56
39.32
20.3
17.87
42.33
21.8
35.76
50.9
Variance
14.4
26.52
175.95
40.9
18.07
15.45
46.01
14.57
42.74
45.63
Market Risk Adjusted Performance
(4.56)
0.4368
(0.05)
(1.36)
0.0181
3.2
(4.07)
3.2
0.1482
1.51
Risk Adjusted Performance
(0.1)
(0.07)
0.0181
(0.16)
0.0078
(0.09)
(0.12)
(0.08)
(0.0004)
(0.04)
Skewness
(0.26)
0.7399
5.23
(1.51)
0.7883
(0.93)
0.583
0.6818
1.11
(1.44)
Semi Deviation
N/A
N/A
5.37
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Information Ratio
(0.18)
(0.13)
0.0058
(0.25)
(0.02)
(0.17)
(0.20)
(0.14)
(0.03)
(0.08)
Value At Risk
(7.69)
(7.37)
(9.34)
(10.14)
(5.71)
(8.40)
(10.57)
(6.25)
(9.05)
(10.70)
Expected Short fall
N/A
N/A
(9.54)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Downside Deviation
N/A
N/A
5.66
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Semi Variance
N/A
N/A
28.88
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Adial Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Adial Pharmaceuticals Competition

Adial Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Adial Pharmaceuticals in relation to its competition. Adial Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Adial Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Adial Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Adial Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Adial Pharmaceuticals position

In addition to having Adial Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Monster Funds Thematic Idea Now

Monster Funds
Monster Funds Theme
Solid funds with above average long term performance indicators based on Macroaxis rating system. The Monster Funds theme has 33 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Monster Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Adial Pharmaceuticals is a strong investment it is important to analyze Adial Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adial Pharmaceuticals' future performance. For an informed investment choice regarding Adial Stock, refer to the following important reports:
How To Invest In Adial
Details
Is Adial Stock a good investment?
Details
What is Adial Pharmaceuticals' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Adial Pharmaceuticals Correlation with its peers.
For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY